Last updated 2026-06-18
- Raised $47.5M funding round led by Khosla Ventures, May 2025
- Raised $5.3M funding round led by TechAviv Founder Partners, Apr 2024
- Raised $4.7M funding round, Sep 2024
Total raised
$57.5M
Last: 2025-05
Stage
Series A
Founded
2023
Headcount
48
HQ
Israel
Sector
Health Tech & Life Sciences
About
Somite.ai is aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle as it enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders.
Funding history · 3 rounds · $57.5M total
2025-05
2024-09
Q&A
- What is Somite.ai's primary focus?
- Somite.ai is developing an AI-based platform to produce human tissue for cell-based therapies, aiming to become a leader in stem cell biology using AI foundation models.
- When was Somite.ai founded?
- Somite.ai was founded in October 2023.
- What is the total amount of funding Somite.ai has raised to date?
- Somite.ai has raised a total of $57,500,000 in funding.
- Which investors participated in Somite.ai's funding round in May 2025?
- In May 2025, Somite.ai raised $47,500,000 in a funding round led by Khosla Ventures, with participation from.
- Which investors participated in Somite.ai's funding round in April 2024?
- In April 2024, Somite.ai raised $5,300,000 in a funding round led by TechAviv Founder Partners, with participation from.
- What is the name of Somite.ai's AI platform?
- Somite.ai's AI platform is named AlphaStem.
- What are some of the diseases Somite.ai's therapies aim to address?
- Somite.ai's cell therapies are being developed for diseases such as diabetes, obesity, and muscular dystrophies, including the SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders.
- How many employees does Somite.ai currently have?
- Somite.ai has an employee count in the 11-50 range.
- Who are the co-founders of Somite.ai?
- The co-founders of Somite.ai include Micha Breakstone (Co-founder & CEO), Olivier Pourquie, Jay Shendure, Allon Klein, Cliff Tabin, and Jonathan Rosenfeld (Co-founder & CTO).
Team · 6
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue Engineering
Technologies
Artificial Intelligence
Target customers
Healthcare & Life SciencesLife SciencesBiotechnology
Business model
B2C
Highlights
Verified
Tags
artificial-intelligencecell-therapystem-cells
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | cellularintelligence.com |
|---|---|
| linkedin.com/company/98835010 |
Identifiers & details
| Founded | 2023-10 |
|---|---|
| Employees (exact) | 48 |
| Offices | Boston |
Radar intelligence
Web history (Wayback)
| Domain | cellularintelligence.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|